抗癌治疗疗效的祖先差异及其潜在的基因组和分子改变。
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.
作者信息
Luo Mei, Yang Jingwen, Schäffer Alejandro A, Chen Chengxuan, Liu Yuan, Chen Yamei, Lin Chunru, Diao Lixia, Zang Yong, Lou Yanyan, Salman Huda, Mills Gordon B, Ruppin Eytan, Han Leng
机构信息
Brown Center for Immunotherapy, School of Medicine, Indiana University, Indianapolis, Indiana.
Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, Indiana.
出版信息
Cancer Discov. 2025 Mar 3;15(3):511-529. doi: 10.1158/2159-8290.CD-24-0827.
Abstract
Our study charts a global landscape of ancestry-associated differences in therapeutic efficacy, highlighting the importance of considering ancestry in anticancer therapies.
摘要
我们的研究描绘了一幅治疗效果中与血统相关差异的全球图景，突出了在抗癌治疗中考虑血统的重要性。
相似文献
1
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.抗癌治疗疗效的祖先差异及其潜在的基因组和分子改变。
Cancer Discov. 2025 Mar 3;15(3):511-529. doi: 10.1158/2159-8290.CD-24-0827.
2
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.泛药物治疗策略：一种基于个体基因组数据对癌症治疗药物进行优先级排序的新方法。
Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.
3
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies.基于遗传血统的精准肿瘤治疗生物标志物合格性差异。
JAMA Oncol. 2025 Mar 1;11(3):310-316. doi: 10.1001/jamaoncol.2024.5794.
4
A decision support framework for genomically informed investigational cancer therapy.用于基于基因组信息的癌症研究性治疗的决策支持框架。
J Natl Cancer Inst. 2015 Apr 11;107(7). doi: 10.1093/jnci/djv098. Print 2015 Jul.
5
The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling.关于综合基因组分析推荐的抗癌药物超说明书用药的日本全国民意调查。
Int J Clin Oncol. 2025 Jul 18. doi: 10.1007/s10147-025-02809-y.
6
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
7
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.为具有可操作改变的非小细胞肺癌患者在整个治疗过程中推动最佳实践：播客讨论
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03195-7.
8
Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment.植物化学物质在癌症治疗中的应用：个性化治疗机制、挑战及进展的结构化综述
Chem Biodivers. 2025 Aug;22(8):e202402479. doi: 10.1002/cbdv.202402479. Epub 2025 Jun 11.
9
Deep learning-driven drug response prediction and mechanistic insights in cancer genomics.深度学习驱动的癌症基因组学中的药物反应预测及机制洞察
Sci Rep. 2025 Jul 1;15(1):20824. doi: 10.1038/s41598-025-91571-2.
10
Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications.螺旋抑素A的抗癌疗效：组蛋白去乙酰化酶抑制作用及肿瘤学应用的当前见解
Eur J Med Res. 2025 Mar 14;30(1):169. doi: 10.1186/s40001-025-02401-0.
引用本文的文献
1
Advancing equitable access to innovation in breast cancer.推进乳腺癌创新的公平可及性。
NPJ Breast Cancer. 2025 Jul 10;11(1):71. doi: 10.1038/s41523-025-00768-1.
2
Spatial and temporal dynamics in progressive gallbladder cancer.进展期胆囊癌的时空动态变化
Nat Genet. 2025 Jun 26. doi: 10.1038/s41588-025-02232-z.
本文引用的文献
1
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.阿法替尼、吉非替尼和厄洛替尼用于初治的表皮生长因子受体突变的老年晚期非小细胞肺癌患者的有效性和安全性：一项多机构回顾性研究。
Aging (Albany NY). 2024 Jan 8;16(1):550-567. doi: 10.18632/aging.205395.
2
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.通过对 187 个新风险变体的多祖裔全基因组发现，描绘前列腺癌风险。
Nat Genet. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9.
3
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.非洲裔肿瘤测序揭示了常见癌症中具有临床意义的改变的差异。
Cancer Cell. 2023 Nov 13;41(11):1963-1971.e3. doi: 10.1016/j.ccell.2023.10.003. Epub 2023 Oct 26.
4
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.量化癌症患者临床可操作性的扩展领域。
Cancer Discov. 2024 Jan 12;14(1):49-65. doi: 10.1158/2159-8290.CD-23-0467.
5
Expanding PROTACtable genome universe of E3 ligases.拓展 E3 连接酶的 PROTAC 可及基因组范围。
Nat Commun. 2023 Oct 16;14(1):6509. doi: 10.1038/s41467-023-42233-2.
6
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study.原发性癌与转移性癌之间的基因差异：一项泛癌全基因组比较研究。
Signal Transduct Target Ther. 2023 Sep 29;8(1):363. doi: 10.1038/s41392-023-01596-0.
7
A multi-omics perspective of CAR T cell therapy.嵌合抗原受体 T 细胞疗法的多组学视角。
Clin Transl Med. 2023 May;13(5):e1274. doi: 10.1002/ctm2.1274.
8
Pan-cancer whole-genome comparison of primary and metastatic solid tumours.泛癌种原发性和转移性实体瘤全基因组比较
Nature. 2023 Jun;618(7964):333-341. doi: 10.1038/s41586-023-06054-z. Epub 2023 May 10.
9
CAR-T Therapies in Solid Tumors: Opportunities and Challenges.嵌合抗原受体 T 细胞疗法在实体瘤中的应用：机遇与挑战。
Curr Oncol Rep. 2023 May;25(5):479-489. doi: 10.1007/s11912-023-01380-x. Epub 2023 Feb 28.
10
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation.三元复合物解离动力学有助于突变体选择性的表皮生长因子受体降解。
Cell Chem Biol. 2023 Feb 8. doi: 10.1016/j.chembiol.2023.01.007.
Zotero 插件